Effect of acupuncture on the prevention of nausea and vomiting after laparoscopic cholecystectomy: a randomized clinical trial / Efeitos da acupuntura para a prevenção de náuseas e vômitos após colecistectomia laparoscópica: estudo clínico randomizado

Abstract Background and objectives: Postoperative nausea and vomiting (PONV) is a common and undesirable complication observed after laparoscopic cholecystectomy (LC). We investigated the effects of auriculoacupuncture (AA) on the prevention of postoperative nausea and vomiting in the immediate postoperative period of uncomplicated laparoscopic cholecystectomy. Methods: Sixty-eight patients were randomly divided into two groups, auriculoacupuncture (n = 35) and control (n = 33), and then they were evaluated prospectively. The needle was placed before anaesthesia induction and remained for 20 minutes. Nausea intensity was evaluated using an analogic visual scale and PONV events were registered immediately after anaesthesia care unit admission and in the second, fourth and sixth hours after the surgery. Results: The auriculoacupuncture group had a significantly smaller incidence of nausea and vomiting than the control group throughout the whole postoperative period (16/35 vs. 27/33, p= 0.03 and 4/35 vs. 15/33, p= 0.005, respectively); the AA group had fewer nausea events 2 h (p= 0.03) and 6 h (p= 0.001) after surgery and fewer vomiting events 2 h (p= 0.01) and 6 h (p= 0.02) after surgery. Conclusions: Auriculoacupuncture can partially prevent postoperative nausea and vomiting when compared to metoclopramide alone after uncomplicated laparoscopic cholecystectomy. Auriculoacupuncture can be recommended as an adjuvant therapy for postoperative nausea and vomiting prevention in selected patients.

Resumo Justificativa e objetivos: Náuseas e vômitos são complicações comuns e indesejáveis no pós-operatório de colecistectomia laparoscópica (CL). Nós investigamos os efeitos da auriculoacupuntura (AA) para a prevenção de náuseas e vômitos no período pós-operatório (NVPO) imediato da CL não complicada. Métodos: 68 pacientes foram aleatoriamente divididos em dois grupos, auriculoacupuntura (n = 35) e controle (n = 33), e foram avaliados prospectivamente. A agulha foi aplicada antes da indução anestésica e permaneceu no lugar por 20 minutos. A intensidade da náusea foi avaliada mediante escala visual analógica e episódios de NVPO foram registrados imediatamente após a admissão na unidade de recuperação anestésica e duas, quatro e seis horas após a cirurgia. Resultados: O grupo AA apresentou significativamente menos episódios de NVPO do que o grupo controle durante todo o período pós-operatório (16/35 vs. 27/33, p = 0,03 e 4/35 vs. 15/33, p = 0,005, respectivamente). O grupo auriculoacupuntura apresentou episódios de náuseas menos intensos às 2 horas (p = 0,03) e 6 horas (p = 0,001) após a cirurgia e menos episódios de vômitos 2 horas (p = 0,01) e 6 horas (p = 0,02) após a cirurgia. Conclusão: A auriculoacupuntura aliviou náuseas e vômitos no pós-operatório em número significante de pacientes, mas não foi capaz de prevenir náuseas e vômitos no pós-operatório em todos os pacientes. Ela pode ser recomendada como terapia adjuvante para prevenção de náuseas e vômitos no pós-operatório no pós-operatório de colecistectomia laparoscópica em pacientes selecionados.

Farmacovigilancia activa de metoclopramida 10 mg oral en pacientes del Programa de Alivio del Dolor y Cuidados Paliativos o diabetes mellitus tipo 2 en cinco hospitales del Servicio de Salud Viña del Mar-Quillota / Extrapyramidal adverse reactions to metoclopramide: a pharmacovigilance survey

Background: In 2013 the Chilean regulatory sanitary agency issued a warning concerning dose adjustment and use restriction to avoid severe adverse effects of metoclopramide such tardive dyskinesia. Aim: To study dyskinesia type adverse effects in a population using metoclopramide. Material and Methods: A cross sectional observational study was conducted among patients pertaining to palliative care and diabetes mellitus programs and consuming 10 mg/day or more of metoclopramide. Patients were interrogated looking for extrapiramidal signs and symptoms using a questionnaire validated by two neurologists. Results: In 40% of diabetic patients with gastroparesia and 35% of palliative care patients, extrapyramidal adverse reactions to metoclopramide were suspected. Palliative Care patients suffered the largest number of adverse events. The period of use and individual doses of the drug were largely above Chilean regulatory agency recommendations in all cases. Conclusions: A significant number of patients using metoclopramide could experience extrapyramidal adverse reactions.

Bromopride, metoclopramide, or ondansetron for the treatment of vomiting in the pediatric emergency department: a randomized controlled trial / Bromoprida, metoclopramida ou ondansetrona no tratamento de vômito no departamento de emergência pediátrica: ensaio controlado randomizado

Abstract Objective: To compare the effectiveness of a single intramuscular dose of bromopride, metoclopramide, or ondansetron for treating vomiting. Methods: Randomized controlled trial including children 1-12 years of age presenting with acute vomiting at the pediatric emergency department. Outcomes: Number of children that stopped vomiting at one, six, and 24 h following treatment; episodes of diarrhea; acceptance of oral liquids; intravenous rehydration; return to hospital and side effects. Results: There were 175 children who completed the study. Within the first hour after treatment, all drugs were equally effective, with ondansetron preventing vomiting in 100%, bromopride in 96.6%, and metoclopramide in 94.8% of children (p = 0.288). Within six hours, ondansetron was successful in preventing vomiting in 98.3% of children, compared to bromopride and metoclopramide, which were successful in 91.5% and 84.4% of patients, respectively (p = 0.023). Within 24 h, ondansetron was superior to both other agents, as it remained efficacious in reducing vomiting in 96.6% of children, as opposed to 67.8% and 67.2% with bromopride and metoclopramide, respectively (p = 0.001). The ondansetron group showed better acceptance of oral liquids (p = 0.05) when compared to the bromopride and metoclopramide. The ondansetron group did not show any side effects in 75.9% of cases, compared to 54.2% and 53.5% in the bromopride and metoclopramide groups, respectively. Somnolence was the most common side effect. Conclusions: A single dose of ondansetron is superior to bromopride and metoclopramide in preventing vomiting six hours and 24 h following treatment. Oral fluid intake after receiving medication was statistically better with Ondansetronwhile also having less side effects compared to the other two agents.

Resumo Objetivo: Para comparar a eficacia de uma unica dose intramuscular de bromoprida, metoclopramida ou ondansetrona no tratamento de vomito. Métodos: Ensaio controlado randomizado incluindo crianc¸as de 1 a 12 anos de idade que apresentam vomito agudo no departamento de emergencia pediatrica. Desfechos: Numero de crianças que pararam de vomitar 1, 6 e 24 horas apos o tratamento; episodios de diarreia; aceitac¸ao de liquidos orais; reidratac¸ao intravenosa, retorno ao hospital e efeitos colaterais. Resultados: 175 crianças concluiram o estudo. Na primeira hora apos o tratamento, todos os medicamentos foram igualmente eficazes, sendo que a ondansetrona preveniu vomito em 100%, a bromoprida em 96,6% e metoclopramida em 94,8% das crianças (p = 0,288). Em 6 horas, a ondansetrona mostrou sucesso na prevençao do vomito em 98,3% das crianças, em comparac¸ao a bromoprida e a metoclopramida, que mostraram sucesso em 91,5% e 84,4% dos pacientes, respectivamente (p = 0,023). Em 24 horas, a ondansetrona foi superior aos dois outros agentes, pois ela continuou eficaz na reduçao do vomito em 96,6% das crianças, diferente de 67,8% e 67,2% com bromoprida e metoclopramida, respectivamente (p = 0,001). O grupo de ondansetrona mostrou melhor aceitaçao de liquidos orais (p = 0,05) em comparaçao a bromoprida e metoclopramida. O grupo de ondansetrona nao mostrou efeitos colaterais em 75,9% dos casos, em comparaçao a 54,2% e 53,5% dos grupos de bromoprida e metoclopramida. O efeito colateral mais comum foi sonolencia. Conclusões: Uma unica dose de ondansetrona e superior a bromoprida e metoclopramida no tratamento de vomito 6 horas e 24 horas apos o tratamento. A ingestao de fluidos orais apos receber medicaçao foi estatisticamente melhor com ondansetrona, ao mesmo tempo em que tambem apresentando menos efeitos colaterais em comparaçao aos outros dois agentes.

Efectos extrapiramidales por metoclopramida en embarazo y recién nacido / Extrapyramidal effects for metoclopramide in pregnancy and newborn

Las náuseas y la emesis son complicaciones posoperatorias que pueden derivar en bronco aspiración, una situación clínica potencialmente fatal. Para su prevención, se usan medicamentos como la metoclopramida. Se presenta un reporte de caso de extrapiramidalismo por metoclopramida en el recién nacido y la madre. Es una reacción secundaria a un medicamento, clasificada como un evento serio y definitivo, de tipo A. Se requiere considerar el balance entre riesgo y beneficio de este medicamento en este tipo de condiciones, como también considerar otras medidas que eviten estos casos. El reporte de reacciones adversas a medicamentos es una actividad que contribuye al uso seguro de los medicamentos.

Postoperative nauseas and vomiting are complications that can lead to bronchoaspiration, a potentially fatal clinical event. Medications such as metoclopramide are used to prevent them. A case report of extrapyramidal signs in a newborn and mother metoclopramide is presented. It has been classified as a serious drug reaction, type A. The risk-benefit balance of this drug in such conditions should be considered as well as other measures to prevent such events. The reporting of adverse drug reactions is an activity that contributes to the safe use of medicines.

Paralytic Ileus and Prophylactic Gastrointestinal Motility Medication after Spinal Operation

PURPOSE: To investigate the prevalence of paralytic ileus after spinal operation in the supine or prone operative position and to determine the efficacy of prophylactic gastrointestinal motility medications in preventing symptomatic paralytic ileus after a spinal operation. MATERIALS AND METHODS: All patients received spinal surgery in the supine or prone operative position. The study period was divided into two phases: first, to analyze the prevalence of radiographic and symptomatic paralytic ileus after a spinal operation, and second, to determine the therapeutic effects of prophylactic gastrointestinal motility medications (postoperative intravenous injection of scopolamine butylbromide and metoclopramide hydrochloride) on symptomatic paralytic ileus after a spinal operation. RESULTS: Basic demographic data were not different. In the first phase of this study, 27 patients (32.9%) with radiographic paralytic ileus and 11 patients (13.4%) with symptomatic paralytic ileus were observed. Radiographic paralytic ileus was more often noted in patients who underwent an operation in the prone position (p=0.044); whereas the occurrence of symptomatic paralytic ileus was not different between the supine and prone positioned patients (p=0.385). In the second phase, prophylactic medications were shown to be ineffective in preventing symptomatic paralytic ileus after spinal surgery [symptomatic paralytic ileus was observed in 11.1% (4/36) with prophylactic medication and 16.7% (5/30) with a placebo, p=0.513]. CONCLUSION: Spinal surgery in the prone position was shown to increase the likelihood of radiographic paralytic ileus occurrence, but not symptomatic paralytic ileus. Unfortunately, the prophylactic medications to prevent symptomatic paralytic ileus after spine surgery were shown to be ineffective.

Ondansetron versus combined dexamethasone and metoclopramide in prevention of nausea and vomiting after laparoscopic cholecystectomy

To compare the efficacy of combined metoclopramide and dexamethasone with ondansetron in preventing nausea and vomiting after laparoscopic cholecystectomy. Randomized controlled trial. Surgical Unit I Combined Military Hospital Rawalpindi, from 1[st] June 2010 to 3[rd] January 2011. A total of 120 patients were observed for 24 hours after elective laparoscopic cholecystectomy for nausea and vomiting and divided into two groups of 60 patients each. Nausea and vomiting was rated by the patients according to a three point scale [O=no nausea and vomiting, 1= nausea, 2= retching or vomiting]. Early postoperative nausea and vomiting was not present in 31[51.7%] patients of group 1 and 40[66.7%] of group 2 [score = 0]. In 11[18.3%] patients of group 1 and 12 [20.0%] of group 2 only nausea was present [score = 1], while 18[30.0%] patients in group 1 and [13.3%] in group 2 scored 2.The late postoperative nausea and vomiting was not present in 21[35.0%] patients in group 1 and 37[61.7%] in group II [score = 0]. In 28 [46.7%] patients in group 1 and 22[36.7%] in group 2 nausea was present [score = 1] while 11[18.3%] patients of group 1 and 1[1.7%] in group 2 scored 2. Ondansetron was effective as compared to combined metoclopramide and dexamethasone in prevention of post-laparoscopic cholecystectomy nausea and vomiting

Beneficio de la goma de mascar vs metoclopramida en la prevención del íleo postoperatorio de laparotomía / Benefit of chewing gum vs metoclopramide in the prevention of postoperative ileus ofter laparotomy

Analizar el beneficio de la goma de mascar y la metoclopramida en la prevención del íleo postoperatorio de laparotomía, Hospital Victorino Santaella Ruíz, octubre-noviembre 2009. Estudio prospectivo, cuasiexpemental. Un total de 60 pacientes post-operados de laparotomía fueron seleccionados y distribuidos equitativamente en 3 grupos: metoclopramida, goma de mascar y grupo control. Se registro el inicio de ruidos hidroaéreos, expulsión de flatos, evacuaciones y tolerancia completa a la vía oral en cada grupo. Los resultados fueron semetidos a un análisis de varianza de una sola vía y test de comparaciones múltiples. Con respecto al grupo control el grupo goma de mascar demostró ventaja al evaluar los factores ruidos hidroaéreos (p<0,05) y tolerancia completa a la vía oral (p<0.02). De la misma manera lo demostró el grupo metoclopramida (p<0,05) sobre el grupo control cuando se evaluó el factor flatos. Y en relación al factor evacuaciones ambos grupos terapéuticos demostraron igual superioridad sobre el grupo control (p<0.02). No se observaron diferencias significativas entre los grupos goma de mascar y metoclopramida. No se observaron diferencias significativas entre la administración de goma de mascar y metoclopramida, sin embargo al compararlos individualmente con el grupo control ambos mostraron beneficios estadísticamente significativos, que fueron mayores cuantitativamente en el grupo goma de mascar. En base a lo anterior y a otras ventajas como; la virtual ausencia de efectos secundarios, su bajo costo, su fácil y amplia disponibilidad, podemos recomendar el uso de goma de mascar para la prevención del íleo postoperatorio.

Analyze the benefit of chewing gum and metoclopramide in the prevention of postoperative ileus after laparotomy, Hospital Victorino Santaella Ruíz, octubre-november 2009. A prospective clinical trial carried out on 60 post-operatives of laparotomy patients. They were randomly assigned into three groups: metoclopramide, chewing gum and control group. The beginning of bowel sounds, flatus, bowel movements and complete food tolerance were recorded in each group. The data were analysed using the one-way variance method and the multiple comparison test. With respect to control group, the chewing gum group showed some statistical advantage when the factor, bowel sounds and complete food tolerance were compared (p<0,05) and (p<0.02) respectively. Metoclopramide showed advantage over the control group in regard to flatus factor (p<0,05). For the bowel movement factor, both therapeutic groups showed identical superiority compared to control group (p<0.02). There was no statistical diference between metoclopramide and chewing gum groups. There were not statistical difference between both therapeutic groups; nevertheless, when both of them were compared individually with the control group, the chewing gum group showed cuantitatively more advantages than metoclopramide group in the prevention of postoperative ileus. Based on the previously describe and other advantages as absence of side effects low cost and easy accessibility we can recommend the use of chewing gum in the prevention of postoperative ileus.

Ondansetron oral frente a metoclopramida dexametasona intravenoso en el control de nauseas y vómitos post-operatorio en pacientes sometidos a anestesia general balanceada en el Hospital Roberto Calderón Gutiérrez en el período julio 2009-diciembre 2009 / Ondansetron oral dexamethasone versus intravenous metoclopramide in controlling nausea and vomiting, post-surgical patients undergoing general anesthesia at the Hospital Calderon Roberto Gutiérrez in the period July 2009-December 2009

La nauseas y los vómitos representan un reto terapeútico importante en los cuidados postoperatorios en la labor del anestesiólogo, en el cual debe de conocer los diferentes esquemas de tratamiento disponibles para tener éxito en el control de las nauseas y vómitos postoperatorio. Se realizó un estudio comparativo para evaluar la eficacia de la presentaciòn oral de Ondasentron 16 mgrs, frente a la asociación de metoclopramida 10 mgrs-dexametasona, en cada grupo se evaluo las características generales, factores de riesgo predisponentes así como el tiempo quirurgico y anestésico. A los pacientes se loes administrò una hora nates de recibir anestesia general el fármaco eleido, en sala de recuparaciòn se vigiló la presencia o ausencia de las nauseas y vómitos en las primeras horas postquirurgicas dándole seguimiento en la siguientes 24 horas. En el grupo que recibiò Ondansetron oral demostró un mejor control en las nauseas y vómitos postooperatorio de anestesia general, que la asociaciòn de metoclopramida-dexametasona, en ambos grupos no se observaron reacciones afversas al fármaco...

Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery.

BACKGROUND: Postoperative nausea and vomiting (PONV) remains a very troublesome concomitant phenomenon after general anesthesia. The present study was designed to compare the efficacy and safety of ondansetron with metoclopramide for prophylaxis of PONV in patients undergoing major gynecological surgery. MATERIAL AND METHOD: A prospective, randomized, double-blind, 382 female patients received either ondansetron 4 mg or metoclopramide 10 mg intravenous administration immediately before the induction of anesthesia. A standard general anesthetic technique was employed throughout. Nausea, vomiting, and safety assessments were performed continuously during the 24 h postoperative period. RESULTS: Of the 380 patients evaluated, significantly fewer ondansetron 4 mg treated patients (89/189; 47%) experienced postoperative nausea and/or vomiting compared with metoclopramide treated patients (115/ 191; 60%) during the study period (p = 0.007, 95% CI: 1.07, 1.66). Postoperative adverse events were not significantly different between the groups. CONCLUSION: Prophylactic use of ondansetron is more effective than metoclopramide for preventing PONV in patients undergoing major gynecological surgery.

Role of metochlopramide and dimenhydrinate in orevention of postoperative nausea and vomiting in laparoscopic gynaecological surgery

To evaluate the role of metoclopramide and dimenhydrinate in controlling postoperative nausea and vomiting [PONV] and its cost effectiveness in gynaecological laparoscopy. This study was conducted in the department of anaesthesiology and intensive care unit, Pakistan Institute of Medical Sciences, Islamabad from June 2004 to March 2006. Ninety nine female patients belonging to American society of Anaesthesiologist [ASA] grading ASA-1 to ASA-111, scheduled for laparoscopic surgery, who did not fall in exclusion criteria were finally included. Anaesthetic technique was standardized for all patients. Injection Metocloparamide 10 mg and injection Dimenhydrinate 50 mg were administered 20 min before the procedure was over. At the end of procedure patients were transferred to the recovery room for observation for 10 hours. Four point verbal descriptive scale [VDS] was used to identify the presence and severity of PONV. Four out of 99 [4.04%] patients developed nausea soon after regaining consciousness and did not demand any medication for relief. Three [3.03%] patients developed vomiting. It was single episode and no rescue medication was needed. Most of the symptoms developed with in 10 -30 minutes of reversal. Metocloparamide and dimenhydrinate is a good combination to combat PONV and is costeffective in laparoscopic gynaecological surgery

Improving paracetamol absorption [oral tablets] by using metoclopramide [single dose]

The aim of this study is to investigate the possibility of improving the rate and extent paracetamol absorption [single oral dose] by increasing rate of gastric emptying by using metoclopramide. So [This makes] paracetamol moves more quickly to the duodenum, which is the preferable site of paracetamol absorption. The study was carried out in twelve healthy male volunteers [Crossover Study]. They were given single oral dose [500 mg paracetamol and 10 mg metoclopramide]. Paracetamol serum concentrations were analyzed by HPLC. Pharmacokinetic parameters were determined by using modified Excel program. The determined parameters were C[max], T[max], AUC, relative F, T[1/2], K, Ka, T[1/2a] and MRT. The results showed improvement in extent of paracetamol absorption when it was given with metoclopramide [F=132 +/- 8%]. They showed also improvement in its absorption rate, which was reflected in decreasing T[max] from 1.333 +/- 0.246 hour to 0.75 hour. Increasing C[max] from 6.458 +/- 1.186 micro g/ml to 12.042 +/- 1.137 micro g/ml, increasing Ka from 1.250 +/- 0.254 to 3.133 +/- 0.250 and decreasing T[1/2a] from 0.581 +/- 0.115 to 0.220 +/- 0.018 hour, which lead to reduction in MRT from 4.467 +/- 0.525 to 3.306 +/- 0.593

effect of adding intravenous Metoclopramide to Pethidine for postoperative cesarean section pain

Pain relief has been received the highest level of medical attempts continuously but still many patients suffer from it. Narcotics' side-effects have led investigators to apply other techniques for controling acute postoperative pain to reduce narcotics requirements. Recently, some concepts have been presented implying that Metoclopramide does have analgesic effects and this led us to conduct the present study in order to determine Metoclopramide's effect on alleviating pain after cesarean section. In this clinical trial, 80 patients who were candidates of elective cesarean section were studied in two groups. 10 minutes before the cesarean section's ending time, the control group was given 25 mg Pethidine accompanied by 10 mg Metoclopramide and control group 25 mg Pethidine and distilled water. Then when patients were conscious after cesarean section, for a period of 6 hours received after-care for their vital signs and side-effects of prescribed drugs. Their pain score [VAS] and nausea rate was measured and if necessary, Pethidine was injected with certain dose. Injection time for first dose of Pethidine and its required amount were recorded in a checklist within first 6 hours after cesarean section. Data was analyzed using ANOVA and T tests. Prescription of Metoclopramide inhaunced analgesic effect of narcotics and a meaningful decrease was found in pain score [p=0.002] and nausea rate [p<0.005]. Injection time for the first dose of Pethidine was also prolonged hi the group who received Metoclopramide compared to control group [p=0.019] and an obvious decrease was occurred in received Pethidine's amount within the first hours after cesarean section [p<0.005]. Drugs side-effects were not found in patients. The results indicate that use of Metoclopramide accompanied by Pethidine in ending time of cesarean section, does have considerable effects in controlling acute pain after surgery and increasing analgesic effect of narcotic drugs. Therefore, use of Metoclopramide as a proper supplement drug with low side-effects is recommended

Comparação de dipirona intravenosa com metoclopramida intravenosa no tratamento de crise aguda de enxaqueca: ensaio clínico randomizado / Comparison of intravenous dipyrone to intravenous metoclopramide in the treatment of acute crisis of migraine: randomized clinical trial

INTRODUÇÃO: A enxaqueca é uma das doenças mais comuns da prática clínica. OBJETIVO: Comparar o efeito analgésico da dipirona com a metoclopramida no alívio da dor. MÉTODO: Conduzimos um estudo piloto randomizado comparando dipirona intravenosa com metoclopramida intravenosa em 27 pacientes apresentando crise de enxaqueca. O objetivo primário foi comparar a redução da intensidade da dor até 2 horas, assim como efeitos colaterais. RESULTADOS: Os grupos tinham faixas etárias semelhantes, mas diferença entre os sexos. Nos homens a metoclopramida reduziu a dor em 80,0 por cento contra 55,0 por cento da dipirona (p=0,052). Já nas mulheres houve uma redução de 65,0 por cento com a metoclopramida e 71,2 por cento com a dipirona (p=0,748). Esses resultados podem ter sido influenciados pelo reduzido número de pacientes no estudo. Não foram encontrados efeitos colaterais significativos. CONCLUSÃO: Não houve diferença quanto à redução da dor nem quanto ao surgimento de efeitos colaterais quando comparados dipirona com metoclopramida.

INTRODUCTION: Migraine is one of the commonest diseases of clinical practice. OBJETIVE: To compare the analgesic effect of dipyrone to metoclopramide in the relief of pain. METHOD: We conducted a pilot randomized study comparing intravenous dipyrone to intravenous metoclopramide in 27 patients presenting acute crisis of migraine. The primary end point was to compare reduction of intensity of pain up to 2 hours, as well as the development of collateral effects. RESULTS: The groups had similar ages, but there were difference between the sexes. In men, metoclopramide reduced pain in 80.0 percent compared with 55.0 percent from dipyrone (p=0.052). In women, there was a reduction of 65.0 percent with metoclopramide and 71.2 percent with dipyrone (p=0.748). The small number of patients in the study might have influenced these results. Significant collateral effects were not found. CONCLUSION: There was no difference about the intensity of pain reduction neither about the development of collateral effects comparing dipyrone to metoclopramide.

Contribution to the treatment of nausea and emesis induced by chemotherapy in children and adolescents with osteosarcoma

CONTEXTO E OBJETIVO: A êmese induzida por quimioterapia é fator limitante no tratamento de crianças com câncer. O uso de quimioterapia com drogas emetogênicas tem aumentado a freqüência desse efeito colateral. O objetivo é comparar a eficácia e a toxicidade do granisetron às da combinação de altas doses de metoclopramida e dimenidrato em crianças com osteossarcoma utilizando a mesma quimioterapia. TIPO DE ESTUDO E LOCAL: Aberto, prospectivo, randomizado, realizado no Instituto de Oncologia Pediátrica, Departamento de Pediatria, Universidade Federal de São Paulo, Brasil. MÉTODOS: Entre fevereiro e agosto de 1994, 26 crianças com idade de 7 a 18 anos (média de 14 anos), recebendo quimioterapia para osteossarcoma, entraram no estudo. A quimioterapia consistiu de ciclos repetidos de: A) ifosfamida 2.500 mg/m² + epirrubicina 75 mg/m²; B) ifosfamida 2.500 mg/m² + carboplatina 600 mg/m²; C) carboplatina 600 mg/m² + epirrubicina 75 mg/m². 80 tratamentos quimioterápicos foram avaliados para o controle de náuse e vômito. Os pacientes foram randomizados para receber dose única de granisetron (50 µ/kg) ou metoclopramida (2 mg/kg) mais dimenidrato (5 mg/kg) infundidos por oito horas. Êmese e náusea foram monitoradas por 24 horas por meio de escore de MANE (Morrow Assessment of Nausea and Emesis). Foram utilizados testes de Qui-quadrado, t e Mann Whitney, além da técnica de análise exploratória de dados. RESULTADOS: O granisetron induziu resposta completa em 62,5% dos pacientes submetidos aos tratamentos quimioterápicos comparado a apenas 10% obtidos com a combinação de metoclopramida associado ao dimenidrato (p < 0,0001). CONCLUSÕES: Concluímos que o granisetron é droga segura e eficiente em crianças com osteossarcoma superior à associação de metoclopramida e dimenidrato no controle de náuseas e vômitos induzidos por quimioterapia para osteossarcoma em crianças.

Efeito da metoclopramida sobre a produção leiteira de porcas no puerpério e o ganho de peso dos leitões / Effect of metoclopramide on sow's milk production and the performance of piglets

A metoclopramida vem sendo utilizada em mulheres como terapia para incremento lactogênico não havendo na literatura informações sobre a utilização desta droga em suínos. O estudo objetivou, avaliar os efeitos da metoclopramida na produção de leite e desempenho da leitegada. Foram utilizadas 12 fêmeas suínas, as quais foram homogeneizadas de acordo com a ordem de parto. A padronização das leitegadas foi estabelecida em 10 leitões por fêmea, totalizando 120 leitões. O delineamento experimental foi inteiramente casualizado caracterizado por medidas repetidas no tempo, sendo definidos dois tratamentos com seis respectivos cada. No tratamento controle (T1) foi feita a aplicação intra-muscular de soro fisiológico nos três primeiros dias pós-parto e no tratamento 2 (T2) foi aplicado metoclopramida. A metoclopramida influenciou significativamente (p < 0,05) na produção de leite, nos três primeiros dias, havendo maior produção em relação ao controle. Não houve diferenças significativas quanto ao ganho de peso dos leitões nas faixas etárias avaliadas, havendo diferença significativa (p < 0,05) no peso dos leitões no 7° dia de vida. Destacou-se no estudo maior homogeneidade e menor dispersão da leitegada proveniente das fêmeas tratadas com metoclopramida, evidenciados pelos valores máximos e mínimos observados aos 21 dias de idade (p < 0,06). Concluiu-se que a metoclopramida provocou aumento do aporte lactacional em fêmeas suínas, nos três primeiros dias de lactação, cujo efeito traduziu-se na melhor homogeneidade da leitegada.

Metoclopramide has been used in humans as a therapy to increase milk production. There is no information available about this drug in swine for the same purpose. The objective of the study was to evaluate the effects of metoclopramide on lactation of swine females and litter development. For this reason 12 females were used in this study. They were assigned in two graups (T1 and T2) and were drug-induced farrowing. T1 females received saline solution during three days after farrowing and T2 group received metoclopramide. The experimental period lasted 42 days starting fram the administration of the drug. Metoclopramide significantly (p <0,05) affected milk praduction at the first three days compared to the control females. Inthe study we found greater homogeneity and smaller dispersion of litter weight fram females treated with metoclopramida, based upon piglet weight at 21 days of age. In conclusion metoclopramide induced higher milk praduction in swine on the first tree days oflactation and affected litter homogeneity.

Effects of Metoclopramide and Ranitidine on Preoperative Gastric Contents in Day-Case Surgery

This prospective, randomized, double-blinded study was performed to evaluate the effects of intravenous metoclopramide and ranitidine on preoperative gastric contents in outpatients receiving intravenous anesthesia for laparoscopic gynecologic surgery. Fifteen minutes before the induction of anesthesia, the Z-M group (n=20) received 50mg ranitidine and 10mg metoclopramide intravenously and the control group (n=20) received the same volume of normal saline. Before the surgery, a 14-F multiorifice nasogastric tube was inserted to aspirate the gastric contents of patients under sedation with propofol and midazolam. The mean pH values of the gastric fluid were 2.7+/-2.0 (SD) [median 1.6 (range: 1.2-7.2)] in the control group, and 6.1+/-1.9 [median 6.8 (range 1.4-7.8)] in the Z-M group. The mean aspirated volumes (mL) were 15.3+/-10.4 (SD) [median 11.0 (range: 5.0-44.0)] in the control group, and 6.9+/-10.0 (SD) [median 4.5 (range: 0-38.0)] in the Z-M group. There were significantly more high-risk (gastric fluid volumes > 25mL and pH < 2.5) patients in the control group (4/20, 20%) than in the Z-M group (1/20, 5%). In conclusion, intravenous prophylactic ranitidine and metoclopramide may be an easy and useful method to decrease the volume while increasing the pH of gastric contents, and therefore may reduce the number of patients at risk for aspiration pneumonitis in ambulatory laparoscopic procedures who receive an anesthesia.

Effects of Metoclopramide and Ranitidine on Preoperative Gastric Contents in Day-Case Surgery

This prospective, randomized, double-blinded study was performed to evaluate the effects of intravenous metoclopramide and ranitidine on preoperative gastric contents in outpatients receiving intravenous anesthesia for laparoscopic gynecologic surgery. Fifteen minutes before the induction of anesthesia, the Z-M group (n=20) received 50mg ranitidine and 10mg metoclopramide intravenously and the control group (n=20) received the same volume of normal saline. Before the surgery, a 14-F multiorifice nasogastric tube was inserted to aspirate the gastric contents of patients under sedation with propofol and midazolam. The mean pH values of the gastric fluid were 2.7+/-2.0 (SD) [median 1.6 (range: 1.2-7.2)] in the control group, and 6.1+/-1.9 [median 6.8 (range 1.4-7.8)] in the Z-M group. The mean aspirated volumes (mL) were 15.3+/-10.4 (SD) [median 11.0 (range: 5.0-44.0)] in the control group, and 6.9+/-10.0 (SD) [median 4.5 (range: 0-38.0)] in the Z-M group. There were significantly more high-risk (gastric fluid volumes > 25mL and pH < 2.5) patients in the control group (4/20, 20%) than in the Z-M group (1/20, 5%). In conclusion, intravenous prophylactic ranitidine and metoclopramide may be an easy and useful method to decrease the volume while increasing the pH of gastric contents, and therefore may reduce the number of patients at risk for aspiration pneumonitis in ambulatory laparoscopic procedures who receive an anesthesia.

Comparative antiemetic efficacy of intrathecal fentanyl and intravenous metoclopromide, during caesarean section under spinal anaesthesia

The aim of this study is to compare the efficacy of intrathecal fentanyl and intravenous metoclopromide for reducing emetic symptoms in parturient undergoing caesarean section under spinal anaesthesia. In a randomized double-blind placebo-controlled study, including 150 American Society of Anesthesiologists [ASA] physical status I,II parturient submitted to bupivacaine spinal anaesthesia for elective caesarean section received either intrathecal fentanyl 20 micrograms [n=49], intravenous metoclopromide 10 mg [n=48] or intravenous saline [n=50]. Drugs were administered depending on their treatment group. Emetic episodes were recorded during and after spinal anaesthesia for caesarean delivery. If intraoperative nausea and vomiting had not subsided completely 5 minutes after giving the study drugs, we treated them with Droperidol. The study was conducted at Queen Alias and Prince Ali Ibn Al Hussein Hospitals between January 2002 and December 2003. Nausea and vomiting occurred in 11.6% of total cases. They were absent in 91.8% of the fentanyl group; 91.6% of the metoclopromide group and 60% of the placebo group [p<0.001 for both the fentanyl and metoclopromide groups versus the placebo group]. Emetic symptoms were more frequent after clamping of the umbilical cord [25.9%] than prior to it [16.3%] p <0.005]. Both intrathecal fentanyl and intravenous metoclopromide were similarly effective; and significantly better than placebo in reducing the incidence and severity of intraoperative emetic symptoms in caesarean section patients under spinal anaesthesia